Clearside Biomedical (CLSD) News Today $0.40 +0.01 (+2.43%) As of 10:31 AM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock CLSD Latest News All Sources Trusted Sources MarketBeat Barchart Benzinga Bloomberg GlobeNewswire GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent August 2025 July 2025 June 2025 May 2025 April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 Time Period Clearside Biomedical Highlights SCS Microinjector® Platform for Retinal Disease Treatment at EURETINA CongressAugust 26 at 8:31 AM | quiverquant.comQClearside Biomedical Announces Multiple Presentations on Suprachoroidal Delivery to be Featured at the 25th EURETINA CongressAugust 26 at 8:05 AM | globenewswire.comClearside Biomedical stock soars after Health Canada approves XIPEREJuly 25, 2025 | in.investing.comClearside Biomedical Receives Canadian Approval for XIPERE® to Treat Uveitic Macular Edema via Suprachoroidal DeliveryJuly 25, 2025 | msn.comClearside Biomedical Announces Approval of XIPERE® Suprachoroidal Treatment for Uveitic Macular Edema in CanadaJuly 23, 2025 | globenewswire.comHC Wainwright & Co. Downgrades Clearside Biomedical (CLSD)July 20, 2025 | msn.comClearside Biomedical Insider Trading Activity | NASDAQ:CLSD | BenzingaJuly 18, 2025 | benzinga.comChardan Capital Downgrades Clearside Biomedical (CLSD)July 18, 2025 | msn.comThis Verint Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For FridayJuly 18, 2025 | benzinga.comClearside to Shift Staff to Consultants, Halt R&D, as It Seeks Strategic AlternativesJuly 18, 2025 | marketwatch.comNeedham Downgrades Clearside Biomedical (CLSD)July 18, 2025 | msn.comClearside Biomedical (NASDAQ:CLSD) Lowered to "Neutral" Rating by Chardan CapitalJuly 18, 2025 | marketbeat.comClearside Biomedical (NASDAQ:CLSD) Stock Rating Lowered by Stifel NicolausJuly 18, 2025 | marketbeat.comClearside Biomedical stock falls after announcing strategic alternatives explorationJuly 17, 2025 | in.investing.comClearside Biomedical Announces Plan to Explore Strategic Alternatives to Advance its Proprietary Suprachoroidal Space (SCS®) Delivery Platform and Promising Ophthalmology PipelineJuly 17, 2025 | globenewswire.comClearside Biomedical (NASDAQ:CLSD) Shares Up 0.3% - Here's What HappenedJuly 7, 2025 | marketbeat.comShareholders in Clearside Biomedical (NASDAQ:CLSD) are in the red if they invested five years agoJune 28, 2025 | finance.yahoo.comClearside Biomedical Announces Multiple Presentations to be Featured at the Clinical Trials at the Summit MeetingJune 17, 2025 | globenewswire.comClearside Biomedical, Inc. (NASDAQ:CLSD) Short Interest Down 44.2% in MayJune 15, 2025 | marketbeat.comClearside Biomedical, Inc. (NASDAQ:CLSD) Given Consensus Recommendation of "Buy" by BrokeragesJune 10, 2025 | marketbeat.comClearside Biomedical (NASDAQ:CLSD) Share Price Crosses Below 50-Day Moving Average - Time to Sell?June 4, 2025 | marketbeat.comHC Wainwright Has Lowered Expectations for Clearside Biomedical (NASDAQ:CLSD) Stock PriceMay 25, 2025 | marketbeat.comClearside Biomedical to Participate in a Fireside Chat at the Stifel 2025 Virtual Ophthalmology ForumMay 21, 2025 | globenewswire.comClearside Biomedical (NASDAQ:CLSD) Raised to Hold at StockNews.comMay 19, 2025 | marketbeat.comClearside Biomedical Announces First Quarter 2025 Financial Results and Provides Corporate UpdateMay 14, 2025 | globenewswire.com7CLSD : A Peek at Clearside Biomedical's Future EarningsMay 14, 2025 | benzinga.comClearside Biomedical Q1 2025 Earnings PreviewMay 14, 2025 | msn.comClearside Biomedical at The Citizens Conference: Strategic Trial InsightsMay 9, 2025 | investing.comClearside Biomedical Data Featured in Six Presentations at Association for Research in Vision and Ophthalmology (ARVO) 2025 MeetingMay 9, 2025 | globenewswire.comClearside Biomedical to Report First Quarter 2025 Financial Results on Wednesday, May 14, 2025May 8, 2025 | globenewswire.comClearside Biomedical (CLSD) Expected to Announce Quarterly Earnings on ThursdayMay 3, 2025 | marketbeat.comClearside Biomedical to Participate in a Fireside Chat at the Citizens Life Sciences ConferenceMay 1, 2025 | globenewswire.comClearside Biomedical (NASDAQ:CLSD) Shares Pass Below Fifty Day Moving Average - What's Next?April 30, 2025 | marketbeat.comClearside Biomedical (NASDAQ:CLSD) Shares Pass Below Fifty Day Moving Average - Here's What HappenedApril 18, 2025 | marketbeat.comNeedham & Company LLC Reaffirms "Buy" Rating for Clearside Biomedical (NASDAQ:CLSD)April 10, 2025 | marketbeat.comHC Wainwright Issues Positive Estimate for CLSD EarningsApril 5, 2025 | marketbeat.comClearside Biomedical’s SWOT analysis: wet AMD stock eyes flexible dosing edgeApril 2, 2025 | uk.investing.comClearside Biomedical (NASDAQ:CLSD) Receives Buy Rating from HC WainwrightApril 1, 2025 | marketbeat.comClearside Biomedical to Participate in a Fireside Chat at the 24th Annual Needham Virtual Healthcare ConferenceApril 1, 2025 | globenewswire.comClearside Biomedical (NASDAQ:CLSD) Earns Buy Rating from Chardan CapitalMarch 29, 2025 | marketbeat.comNeedham & Company LLC Cuts Clearside Biomedical (NASDAQ:CLSD) Price Target to $4.00March 29, 2025 | marketbeat.comClearside Biomedical, Inc.: Clearside Biomedical Announces Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate UpdateMarch 28, 2025 | finanznachrichten.deStifel Nicolaus Sticks to Its Buy Rating for Clearside Biomedical (CLSD)March 28, 2025 | markets.businessinsider.comClearside Biomedical price target lowered to $4 from $6 at NeedhamMarch 28, 2025 | markets.businessinsider.comClearside Biomedical (NASDAQ:CLSD) Issues Quarterly Earnings ResultsMarch 28, 2025 | marketbeat.comClearside Biomedical, Inc. (CLSD) Q4 2024 Earnings Conference Call TranscriptMarch 27, 2025 | seekingalpha.comClearside Biomedical Announces Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate UpdateMarch 27, 2025 | globenewswire.comExploring Clearside Biomedical's Earnings ExpectationsMarch 27, 2025 | benzinga.comClearside Biomedical Announces Six Abstracts Accepted for Presentation at Association for Research in Vision and Ophthalmology (ARVO) 2025 MeetingMarch 24, 2025 | globenewswire.comClearside Biomedical announces presentations on CLS-AXMarch 21, 2025 | markets.businessinsider.com Get Clearside Biomedical News Delivered to You Automatically Sign up to receive the latest news and ratings for CLSD and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. CLSD Media Mentions By Week CLSD Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. CLSD News Sentiment▼1.290.99▲Average Medical News Sentiment CLSD News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. CLSD Articles This Week▼32▲CLSD Articles Average Week Get the Latest News and Ratings for CLSD and Related Stocks Enter your email address to receive the latest news and analysts' ratings for Clearside Biomedical and its competitors. Sign Up View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. Related Companies and Tools Related Companies Protalix BioTherapeutics News Today Protara Therapeutics News Today Corbus Pharmaceuticals News Today Oncobiologics News Today Coya Therapeutics News Today IO Biotech News Today Equillium News Today Adagene News Today Biomea Fusion News Today Anebulo Pharmaceuticals News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:CLSD) was last updated on 8/28/2025 by MarketBeat.com Staff From Our PartnersBuffett, Gates and Bezos Quietly Dumping Stocks—Here's WhyImagine a bull market so powerful, every single investor became a millionaire. Not by finding the next NVIDIA ...Banyan Hill Publishing | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredA New Way to Double Your Retirement Income?Bloomberg reports that a new class of investments is “entering a golden era,” with yields fueling a retail boo...Investors Alley | SponsoredWhat Steve Bannon revealed about Trump’s gold playA Trump advisor just said 3 words that could reset the dollar. It’s a gold move nobody saw coming—and your ...Reagan Gold Group | SponsoredHow “Trump’s New Dollar” Could Impact Your WealthPresident Trump just signed a game-changing law… That could soon upgrade the U.S. dollar in your checking a...Brownstone Research | SponsoredThis strange black card is showing up across America"THIS is the Biggest Economic Story of 2025" While most Americans are focused on tariffs and inflation, the...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Clearside Biomedical, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Clearside Biomedical With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access